Keros Therapeutics, Inc. (KROS) insider trading

By person

20 insiders · 0 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Jasbir Seehra

Chief Executive Officer

—

440,708

$4.54M

+74.3%

Julius Knowles

Director

—

113,191

$1.17M

−73.4%

Christopher Rovaldi

Chief Operating Officer

—

60,000

$618.00K

—

Carl L Gordon

Director

—

50,307

$518.16K

−80.6%

Annita Tanini

Corp. Controller & VP, Finance

—

45,144

$464.98K

−2.6%

Orbimed Advisors LLC entity

Director

—

45,057

$464.09K

−82.6%

Yung H. Chyung

Chief Medical Officer

—

44,000

$453.20K

—

Keith Regnante

Chief Financial Officer

—

39,261

$404.39K

—

Esther Cho

Chief Legal Officer

—

35,770

$368.43K

−20.5%

Lorena Raquel Lerner

Chief Scientific Officer

—

27,559

$283.86K

−21.3%

Jean Jacques Bienaime

Director

—

19,592

$201.80K

+9,696%

Anne Prener

Director

—

13,786

$142.00K

—

Mary Ann Gray

Director

—

12,392

$127.64K

—

Charles W. Newton

Director

—

12,114

$124.77K

—

Alpna Seth

Director

—

9,767

$100.60K

—

Nima Farzan

Director

—

9,767

$100.60K

—

Ran Nussbaum

Director

—

5,250

$54.08K

—

Tomer Kariv

Director

—

5,250

$54.08K

—

Pontifax Management 4 G.P. (2015) Ltd. entity

10% owner

—

$0.00

−100.0%

ADAR1 Capital Management, LLC entity

10% owner

—

$0.00

−100.0%

No percentages here. This company's share count has moved by a factor of 2.1 over the window, from 19,717,533 to 40,615,414 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Keros Therapeutics, Inc.

What the insiders did No buying or selling

By person